Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SECON OF NEW ENGLAND LLC

NPI: 1487659694 · WORCESTER, MA 01608 · Clinical Medical Laboratory · NPI assigned 06/15/2005

$8.88M
Total Medicaid Paid
223,611
Total Claims
108,852
Beneficiaries
15
Codes Billed
2018-01
First Month
2024-10
Last Month

Provider Details

Authorized OfficialFREEMAN, SYLVIA (MGR OF CREDENTIALING/ENROLLMENT)
NPI Enumeration Date06/15/2005

Related Entities

Other providers sharing the same authorized official: FREEMAN, SYLVIA

ProviderCityStateTotal Paid
REGIONAL TOXICOLOGY SERVICES, LLC TACOMA WA $60.35M
AMERICAN FORENSIC TOXICOLOGY SERVICES LLC HUNTINGTON NY $33.21M
ROCKY MOUNTAIN TOX, LLC AURORA CO $236K
TECHNICAL RESOURCE MANAGEMENT LLC INDIANAPOLIS IN $119.72

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 89,239 $3.63M
2019 105,609 $4.05M
2020 26,911 $1.16M
2021 148 $7K
2022 742 $11K
2023 712 $14K
2024 250 $10K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 110,963 51,797 $3.82M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 85,162 40,587 $3.36M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 25,151 14,985 $1.58M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,274 895 $94K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 100 89 $14K
81025 775 326 $4K
82570 55 51 $32.39
80365 13 12 $0.00
80325 13 12 $0.00
80346 16 15 $0.00
80354 13 12 $0.00
83986 26 24 $0.00
80349 13 12 $0.00
80353 13 12 $0.00
84311 24 23 $0.00